Skip to content
← Tools / Skills
ToolSkinVision/10 trustVerified

SkinVision

Smartphone app that risk-assesses moles for skin cancer signs.

Visit official site →

About

SkinVision lets users photograph a mole and receive an AI risk rating (low, medium, high) within about 30 seconds, with mole tracking over time and high-risk cases routed to an in-house dermatologist review. It is CE-marked as a medical device in Europe (EU MDR Class IIa) and is not FDA-cleared, so it is unavailable in the US and Canada.

Accuracy claims deserve caution: a Cochrane-linked review of the available studies found 80% sensitivity and 78% specificity across two small studies and rated the evidence base poor. Treat it as a triage aid, never a diagnosis — a high-risk rating means see a specialist.

What it can do

  • AI mole risk assessment (low/medium/high) from a smartphone photo
  • Mole tracking and change monitoring over time
  • Dermatologist review for high-risk assessments
  • UV index information and skin-health reminders
  • Insurance partnerships in several European countries

Setup

  1. Download the SkinVision app from the App Store or Google Play
  2. Create an account
  3. Answer the skin-type questionnaire
  4. Photograph a mole following the in-app guidance
  5. Receive the risk rating within 30 seconds
  6. Track moles over time; book a dermatologist visit on any high-risk result

Prerequisites

Compatible iOS or Android smartphone; not intended for users under 18.

Use cases

imagedata

Works with

Any agent (.md)

Trust score — 6/10

/10 trustVerified

Scored 6/10 (verified tier, metrics-v1). Evidence: 6M+ skin checks, 50K+ cancers detected (company-reported); CE Class IIa in EU, not FDA-cleared, no US availability.; Cochrane-linked review found poor evidence base: 80% sens / 78% spec across 2 small studies.; Triage aid only; high-risk result requires dermatologist visit.. License: Proprietary medical device app; ISO 27001/13485 certified per vendor..

How the trust score is built

Full methodology →
Adoption · stars/downloads, log-scaled vs peers
7.0/10
Maintenance · recency, releases, issue load
8.0/10
Openness · license + docs
6.0/10
Manual review · sanity read + red-flag check
6.0/10
  • · 6M+ skin checks, 50K+ cancers detected (company-reported); CE Class IIa in EU, not FDA-cleared, no US availability.
  • · Cochrane-linked review found poor evidence base: 80% sens / 78% spec across 2 small studies.
  • · Triage aid only; high-risk result requires dermatologist visit.

Sources

Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.